A 24-week treatment with bofanglutide for patients with type 2 diabetes showed meaningful glycemic control, weight loss, and improvements in cardiometabolic risk factors — reductions which seemed at ...

HHS terminates COVID-19 Emergency Use Authorizations for drugs, biologics, and devices, establishing transition timelines toward traditional FDA pathways.

Metformin does not significantly reduce the risk for long COVID at 6 months in low-risk adults with high baseline immunity to the virus.

Survivors of hematologic cancers face a higher risk of developing cardiovascular disease, according to study results.

Better maternal CVH is associated with lower risk for offspring developmental delay at age 4 years, according to study results.

Younger adults are more susceptible to asymptomatic rhinovirus infections, whereas older adults are more likely to experience respiratory symptoms.

A surge in tetracycline resistance reduces the clinical benefit of doxycycline PEP against gonorrhea in high-risk populations.

The CDC released updated operational guidance for investigating locally-acquired mosquito-transmitted malaria in the US.

An FDA panel voted 9-0 that the benefits of Moderna’s mRNA-1010 flu vaccine outweigh risks for adults aged 50 and older.

Among patients with IDU-related IE, initiation of MOUD is associated with a significant reduction in 30-day all-cause mortality, though optimizing care delivery models remains essential for sustaining ...

Genetically predicted lower systolic blood pressure is associated with an increased susceptibility to allergic rhinitis.

Metformin use may lower the risk for a composite of hospitalization, ED visits, or death in adult patients with acute COVID-19.